remimazolam and Laryngeal-Edema

remimazolam has been researched along with Laryngeal-Edema* in 1 studies

Other Studies

1 other study(ies) available for remimazolam and Laryngeal-Edema

ArticleYear
Laryngeal edema following remimazolam-induced anaphylaxis: a rare clinical manifestation.
    BMC anesthesiology, 2023, 03-29, Volume: 23, Issue:1

    Remimazolam is an ultra-short-acting intravenous benzodiazepine, which has been used as sedative/anesthetic in procedural sedation and anesthesia. Although peri-operative anaphylaxis due to remimazolam has been reported recently, the spectrum of the allergic reactions is still not fully known.. We describe a case of anaphylaxis following remimazolam administration in a male patient undergoing colonoscopy under procedural sedation. The patient presented complex clinical signs including airway changes, skin symptoms, gastrointestinal manifestations and hemodynamic fluctuations. Different from other reported cases, laryngeal edema was the initial and main clinical feature of remimiazolam-induced anaphylaxis.. Remimazolam-induced anaphylaxis has a rapid onset and complex clinical features. This case reminds anesthesiologists should be particularly alert to the unknown adverse reactions of new anesthetics.

    Topics: Adult; Anaphylaxis; Benzodiazepines; Humans; Hypnotics and Sedatives; Laryngeal Edema; Male

2023